Autonomix Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2024. This is an annual report, not a calendar fourth-quarter filing. Autonomix is a pre-revenue, development-stage medical-device company developing catheter-based technology to sense and treat peripheral nervous-system disorders.
Financial performance and position
- Revenue: No revenue in fiscal 2024 or 2023; the company has no approved products.
- Net loss: $15.4 million in fiscal 2024 versus $2.0 million in fiscal 2023. Basic and diluted loss per share was $1.05 versus $0.17.
- Expenses: Operating expenses were $12.0 million, up 505% from $2.0 million. General and administrative expense rose to $5.2 million from $1.2 million; research and development rose to $2.2 million from $0.7 million. The 2024 total included $4.6 million of warrant expense related to a license termination agreement.
- Other expense: A $3.4 million non-cash warrant-liability fair-value charge contributed to the loss. Interest expense was less than $0.1 million; interest income was $0.1 million.
- Cash flow: Operating activities used $6.6 million, versus $1.9 million in 2023. Investing activities used $19,000. Financing activities provided $14.4 million, primarily from the IPO, private stock sales and convertible notes.
- Liquidity: At March 31, 2024, cash was $8.6 million, current assets $9.4 million, current liabilities $0.8 million and working capital approximately $8.6 million.
- Debt: Convertible notes had $1.33 million principal outstanding at year-end, with a $1.00 million net carrying value after discount. The notes are non-interest-bearing, mature December 31, 2025, and carry an effective interest rate of 15.3% due to discount amortization. Some notes converted at the IPO; conversion limits left $1.3 million principal outstanding.
- Equity financing: The January 2024 IPO sold about 2.23 million shares at $5.00 per share, generating $11.2 million gross and $9.8 million net proceeds. The company also raised $2.8 million from a private stock sale.
Changes versus the prior year
- Net loss increased by $13.4 million, reflecting higher operating costs and new warrant-related charges; the warrant charges were non-cash.
- Operating cash use increased by approximately $4.8 million. Year-end cash increased from $0.9 million to $8.6 million, largely following equity and debt financing.
- The company completed its IPO, issued convertible notes and warrants, and reported 2.0 million stock options granted during the year.
- The company corrected an immaterial prior-period classification error, moving $88,000 of fiscal 2023 expenses from general and administrative to research and development. The correction did not change fiscal 2023 net loss, balance sheet, cash flows or earnings per share.
Business outlook, risks and unusual items
- Runway and funding: Management estimates available cash will fund operations into, but not beyond, the first calendar quarter of 2025. It estimates approximately $40 million of additional financing is needed through initial commercial launch. There is no assurance financing will be available; failure to raise capital could force reductions or suspension of operations.
- Going concern: The auditor and management cite substantial doubt about the company’s ability to continue as a going concern. The financial statements do not include adjustments that might result if the company cannot continue operating.
- Development plans: The initial target is pain associated with pancreatic cancer. The company reported that an overseas ethics committee approved its first-in-human proof-of-concept trial of transvascular ablation, conducted without the company’s sensing system. It plans to use trial data in discussions with the FDA; the FDA may require additional or different studies.
- Timeline: Management projects human-clinical sensing-device development by mid-2025, commercial scale-up by mid-2027 and potential FDA clearance in the first half of 2027. These are estimates, not guarantees. The company describes de novo as a likely regulatory pathway, while also discussing possible 510(k) or PMA requirements.
- Technology and execution: The claimed 3,000-times-greater sensitivity is based on company comparisons and has not been established in human trials. The current sensing prototype is hand-built; commercial manufacturing capability and clinical performance remain unproven.
- Related-party warrant: In connection with terminating a cardiovascular technology license, the company issued a warrant for 1.6 million shares at a $0.001 exercise price, representing an $8.0 million value at the IPO price. A director holds a 20% interest in the recipient company. The warrant generated $4.6 million of initial expense and $3.4 million of fair-value expense before reclassification to equity.
- Controls: Management concluded disclosure controls were ineffective and identified material weaknesses involving segregation of duties, general technology controls and financial-statement reporting. Management is working on remediation; the auditor did not attest to internal-control effectiveness.
- Other risks: The company relies on third parties, including a single manufacturer; has no reimbursement codes for its products; faces regulatory, clinical-trial, supply, intellectual-property, cybersecurity and future financing risks. No material pending legal proceedings were reported.
Key facts investors should verify
- Current cash, subsequent spending and financing activity, and whether the stated first-quarter 2025 runway remains valid.
- Whether the company can raise the estimated $40 million and the expected dilution, warrant exercises and remaining note conversions.
- Proof-of-concept trial status, patient enrollment, safety and efficacy results, and FDA feedback on data acceptability and the regulatory pathway.
- Progress toward a human-use sensing catheter, manufacturing qualification and the stated development and clearance timelines.
- Remediation of material weaknesses and any effects on the reliability of future financial reporting.
- The terms, accounting and potential dilution from the 1.6 million-share related-party warrant, and the timing of its exercise or resale registration.
- The filing gives different IPO closing dates in different sections (January 26 and January 29, 2024); verify the applicable closing date and related transaction disclosures.